サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1767752

感染症体外診断の世界市場：製品タイプ別、エンドユーザー別、地域別、産業分析、規模、シェア、成長、動向、予測（2025年～2032年）

Infectious Disease In-vitro Diagnostics Market by Product Type, End-Users, and Geography: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 188 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
感染症体外診断の世界市場：製品タイプ別、エンドユーザー別、地域別、産業分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年07月09日
発行: Persistence Market Research
ページ情報: 英文 188 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

重要な知見

  • 感染症IVDの市場規模（2025年）：466億米ドル
  • 予測される市場金額（2032年）：641億米ドル
  • 世界市場の成長率：4.7%（2025年～2032年のCAGR）

感染症体外診断市場 - レポート範囲

感染症体外診断は、HIV、肝炎、インフルエンザ、結核、SARS-CoV-2のような新興ウイルスの脅威などの感染症の原因となる病原体を迅速かつ正確に検出する上で重要な役割を果たしています。これらの診断には、分子アッセイ、免疫アッセイ、ポイントオブケア検査技術が含まれ、早期診断を可能にし、治療方針の決定を導き、感染制御の取り組みを促進します。感染症IVD市場は、病院、臨床検査室、診断センター、ポイントオブケアに対応し、多様な検査キット、試薬、器具、ソフトウェアソリューションを提供しています。市場成長の促進要因は、感染症の流行、迅速かつ正確な検査に対する需要の増加、診断プラットフォームの技術的進歩による感度、特異度、所要時間の改良です。

市場成長の促進要因

世界の感染症IVD市場は、世界の感染症罹患率の増加、早期発見と疾病管理に対する意識の高まりなどの複数の要因に後押しされています。抗生物質耐性感染症の増加、発生シナリオにおける正確な診断の必要性、感染症サーベイランスとスクリーニングを支援する政府の強力な取り組みが市場成長をさらに加速しています。次世代シーケンシングやマルチプレックスPCRなど、分子診断学における技術の進歩は複数の病原体の同時検出を可能にし、臨床上の意思決定や患者の転帰を向上させます。さらに、分散化した医療環境における感染症スクリーニングへのポイントオブケア検査の使用の拡大は、特に資源が限られた地域において、利便性と迅速な診断を提供し、市場拡大に大きく寄与しています。

市場抑制要因

有望な成長が見込まれる一方、感染症IVD市場は、厳しい規制枠組み、複雑な承認プロセス、特定の地域における償還の制限に関連する課題に直面しています。国によって規制要件が異なるため、世界的な市場浸透の障壁となり、メーカーにとっては開発期間とコストが増大します。さらに、先進の分子診断システムや検査は高価であるため、特に予算の制約が医療費に影響する中低所得国で採用が制限される可能性があります。さらに、検査精度、偽陽性または偽陰性の結果、分散化した環境における品質管理に関する懸念は、診断の信頼性と臨床的信用を維持しようと努める市場参入企業にとって継続的な課題となっています。

市場機会

感染症IVD市場は、技術革新、世界的な健康の優先度、進化する診断ニーズによって大きな成長機会がもたらされます。クラウドベースのデータ管理やAI主導の診断アルゴリズムなどのデジタルヘルスツールの統合により、診断精度が向上し、遠隔分析が可能になり、疾病サーベイランスや発生の追跡がサポートされます。さらに、新しいバイオマーカー、迅速診断検査、シンドロミック検査パネルの研究開発への投資の高まりは、市場の範囲を拡大し、臨床アンメットニーズに対応します。個別化医療へのシフト、官民連携の増加、新たな感染症への備えの重視は、市場企業が革新的なソリューションを開発し、ダイナミックな感染症診断情勢において市場プレゼンスを強化する道筋を作り出しています。

当レポートでは、世界の感染症体外診断市場について調査し、成長促進要因、動向、機会、課題などの市場力学の詳細な分析を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主要動向
  • マクロ経済要因
    • 世界の部門の見通し
    • 世界のGDP成長の見通し
  • COVID-19の影響の分析
  • 予測要因 - 関連性と影響

第3章 付加価値考察

  • 規制情勢
  • 製品採用分析
  • バリューチェーン分析
  • 主な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の感染症体外診断市場の見通し

  • 主なハイライト
    • 市場規模と前年比成長
    • 絶対的収益機会
  • 市場規模の分析と予測
    • 市場規模の実績の分析（2019年～2024年）
    • 現在の市場規模の分析と予測（2025年～2032年）
  • 世界の感染症体外診断市場の見通し：製品タイプ別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：製品タイプ別（2019年～2024年）
    • 現在の市場規模の分析と予測：製品タイプ別（2025年～2032年）
      • 器具
      • 試薬
      • ソフトウェア、サービス
    • 市場の魅力分析：製品タイプ別
  • 世界の感染症体外診断市場の見通し：技術
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：技術別（2019年～2024年）
    • 現在の市場規模の分析と予測：技術別（2025年～2032年）
      • イムノアッセイ
      • 分子診断
      • 微生物学
      • その他
    • 市場の魅力分析：技術
  • 世界の感染症体外診断市場の見通し：用途
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：用途別（2019年～2024年）
    • 現在の市場規模の分析と予測：用途別（2025年～2032年）
      • MRSA
      • クロストリジウムディフィシル
      • 呼吸器ウイルス
      • 結核、薬剤耐性結核
      • 淋病
      • HPV
      • HIV
      • C型肝炎
      • B型肝炎
      • COVID-19
      • その他
    • 市場の魅力分析：用途
  • 世界の感染症体外診断市場の見通し：エンドユーザー
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：エンドユーザー別（2019年～2024年）
    • 現在の市場規模の分析と予測：エンドユーザー別（2025年～2032年）
      • ポイントオブケア
      • 中央検査室
      • その他
    • 市場の魅力分析：エンドユーザー

第5章 世界の感染症体外診断市場の見通し：地域

  • 主なハイライト
  • 市場規模の実績の分析：地域別（2019年～2024年）
  • 現在の市場規模の分析と予測：地域別（2025年～2032年）
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の感染症体外診断市場の見通し

第7章 欧州の感染症体外診断市場の見通し

第8章 東アジアの感染症体外診断市場の見通し

第9章 南アジア・オセアニアの感染症体外診断市場の見通し

第10章 ラテンアメリカの感染症体外診断市場の見通し

第11章 中東・アフリカの感染症体外診断市場の見通し

第12章 競合情勢

  • 市場シェア分析（2025年）
  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル（詳細 - 概要、財務、戦略、近年の発展）
    • QIAGEN
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc. (Gen Probe)
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.
    • その他

第13章 付録

目次
Product Code: PMRREP33205

Persistence Market Research has recently released a comprehensive report on the worldwide market for infectious disease in-vitro diagnostics (IVD). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global infectious disease IVD market from 2025 to 2032.

Key Insights:

  • Infectious Disease IVD Market Size (2025E): USD 46.6 Billion
  • Projected Market Value (2032F): USD 64.1 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

Infectious disease in-vitro diagnostics play a crucial role in the rapid and accurate detection of pathogens responsible for infections such as HIV, hepatitis, influenza, tuberculosis, and emerging viral threats like SARS-CoV-2. These diagnostics encompass molecular assays, immunoassays, and point-of-care testing technologies, enabling early diagnosis, guiding treatment decisions, and facilitating infection control efforts. The infectious disease IVD market caters to hospitals, clinical laboratories, diagnostic centers, and point-of-care settings, offering a diverse array of test kits, reagents, instruments, and software solutions. Market growth is driven by the rising prevalence of infectious diseases, increased demand for rapid and accurate testing, and technological advancements in diagnostic platforms, improving sensitivity, specificity, and turnaround times.

Market Growth Drivers:

The global infectious disease IVD market is propelled by several key factors, including the growing incidence of infectious diseases worldwide and heightened awareness of early detection and disease management. The increasing burden of antibiotic-resistant infections, the need for precise diagnostics in outbreak scenarios, and robust government initiatives supporting infectious disease surveillance and screening further accelerate market growth. Technological progress in molecular diagnostics, such as next-generation sequencing and multiplex PCR, enables simultaneous detection of multiple pathogens, enhancing clinical decision-making and patient outcomes. Moreover, the expanding use of point-of-care tests for infectious disease screening in decentralized healthcare settings contributes significantly to market expansion, offering convenience and faster diagnosis, especially in resource-limited regions.

Market Restraints:

Despite promising growth prospects, the infectious disease IVD market faces challenges related to stringent regulatory frameworks, complex approval processes, and reimbursement limitations in certain regions. Variations in regulatory requirements across countries create barriers for global market penetration and increase development timelines and costs for manufacturers. Additionally, the high cost of advanced molecular diagnostic systems and tests can restrict adoption, particularly in low- and middle-income countries where budget constraints affect healthcare spending. Moreover, concerns around test accuracy, false-positive or false-negative results, and quality control in decentralized settings pose ongoing challenges for market players striving to maintain diagnostic reliability and clinical trust.

Market Opportunities:

The infectious disease IVD market presents significant growth opportunities driven by technological innovations, global health priorities, and evolving diagnostic needs. The integration of digital health tools, such as cloud-based data management and artificial intelligence-driven diagnostic algorithms, improves diagnostic accuracy, enables remote analysis, and supports disease surveillance and outbreak tracking. Furthermore, rising investment in research and development for novel biomarkers, rapid diagnostic tests, and syndromic testing panels expands the market scope and addresses unmet clinical needs. The shift toward personalized medicine, increased public-private collaborations, and growing emphasis on preparedness for emerging infectious diseases create avenues for market players to develop innovative solutions and strengthen market presence in the dynamic infectious disease diagnostics landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the infectious disease IVD market globally?
  • Which test types and applications are driving the adoption of infectious disease diagnostics across various healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the infectious disease IVD market?
  • Who are the key players contributing to the infectious disease IVD market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global infectious disease IVD market?

Competitive Intelligence and Business Strategy:

These companies invest in R&D to develop high-sensitivity molecular assays, multiplexed platforms, and rapid point-of-care diagnostics, addressing diverse infectious disease testing needs. Partnerships with healthcare providers, governments, and international health organizations facilitate access to markets, especially during public health emergencies. Moreover, emphasis on automation, integration of digital solutions, and adherence to regulatory standards enables market leaders to deliver reliable, scalable, and cost-effective diagnostic solutions. Continuous efforts in clinical research, assay validation, and global distribution networks further consolidate the competitive landscape in the rapidly evolving infectious disease IVD market.

Key Companies Profiled:

  • QIAGEN
  • Becton, Dickinson and Company
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc. (Gen Probe)
  • Abbott
  • Quidel Corporation
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • OraSure Technologies, Inc.

Infectious Disease IVD Market Research Segmentation:

The infectious disease IVD market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various pathogens and patient populations.

By Product Type

  • Instruments
  • Reagents
  • Software and Services

By Technology

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology
  • Others

By Application

  • MRSA
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others

By End User

  • Point-of-care
  • Central Laboratories
  • Others

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Infectious Disease In-vitro Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Infectious Disease In-vitro Diagnostics Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Infectious Disease In-vitro Diagnostics Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
      • 4.3.3.1. Instruments
      • 4.3.3.2. Reagents
      • 4.3.3.3. Software and Services
    • 4.3.4. Market Attractiveness Analysis: Product Type
  • 4.4. Global Infectious Disease In-vitro Diagnostics Market Outlook: Technology
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
      • 4.4.3.1. Immunoassay
      • 4.4.3.2. Molecular Diagnostics
      • 4.4.3.3. Microbiology
      • 4.4.3.4. Others
    • 4.4.4. Market Attractiveness Analysis: Technology
  • 4.5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Application
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.5.3.1. MRSA
      • 4.5.3.2. Clostridium Difficile
      • 4.5.3.3. Respiratory Virus
      • 4.5.3.4. TB and Drug-resistant TB
      • 4.5.3.5. Gonorrhea
      • 4.5.3.6. HPV
      • 4.5.3.7. HIV
      • 4.5.3.8. Hepatitis C
      • 4.5.3.9. Hepatitis B
      • 4.5.3.10. COVID-19
      • 4.5.3.11. Others
    • 4.5.4. Market Attractiveness Analysis: Application
  • 4.6. Global Infectious Disease In-vitro Diagnostics Market Outlook: End User
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.6.3.1. Point-of-care
      • 4.6.3.2. Central Laboratories
      • 4.6.3.3. Others
    • 4.6.4. Market Attractiveness Analysis: End User

5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Infectious Disease In-vitro Diagnostics Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product Type
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 6.4.1. Instruments
    • 6.4.2. Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 6.5.1. Immunoassay
    • 6.5.2. Molecular Diagnostics
    • 6.5.3. Microbiology
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.6.1. MRSA
    • 6.6.2. Clostridium Difficile
    • 6.6.3. Respiratory Virus
    • 6.6.4. TB and Drug-resistant TB
    • 6.6.5. Gonorrhea
    • 6.6.6. HPV
    • 6.6.7. HIV
    • 6.6.8. Hepatitis C
    • 6.6.9. Hepatitis B
    • 6.6.10. COVID-19
    • 6.6.11. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.7.1. Point-of-care
    • 6.7.2. Central Laboratories
    • 6.7.3. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Infectious Disease In-vitro Diagnostics Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product Type
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 7.4.1. Instruments
    • 7.4.2. Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 7.5.1. Immunoassay
    • 7.5.2. Molecular Diagnostics
    • 7.5.3. Microbiology
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.6.1. MRSA
    • 7.6.2. Clostridium Difficile
    • 7.6.3. Respiratory Virus
    • 7.6.4. TB and Drug-resistant TB
    • 7.6.5. Gonorrhea
    • 7.6.6. HPV
    • 7.6.7. HIV
    • 7.6.8. Hepatitis C
    • 7.6.9. Hepatitis B
    • 7.6.10. COVID-19
    • 7.6.11. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.7.1. Point-of-care
    • 7.7.2. Central Laboratories
    • 7.7.3. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Infectious Disease In-vitro Diagnostics Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product Type
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 8.4.1. Instruments
    • 8.4.2. Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 8.5.1. Immunoassay
    • 8.5.2. Molecular Diagnostics
    • 8.5.3. Microbiology
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.6.1. MRSA
    • 8.6.2. Clostridium Difficile
    • 8.6.3. Respiratory Virus
    • 8.6.4. TB and Drug-resistant TB
    • 8.6.5. Gonorrhea
    • 8.6.6. HPV
    • 8.6.7. HIV
    • 8.6.8. Hepatitis C
    • 8.6.9. Hepatitis B
    • 8.6.10. COVID-19
    • 8.6.11. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.7.1. Point-of-care
    • 8.7.2. Central Laboratories
    • 8.7.3. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Infectious Disease In-vitro Diagnostics Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product Type
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 9.4.1. Instruments
    • 9.4.2. Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 9.5.1. Immunoassay
    • 9.5.2. Molecular Diagnostics
    • 9.5.3. Microbiology
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.6.1. MRSA
    • 9.6.2. Clostridium Difficile
    • 9.6.3. Respiratory Virus
    • 9.6.4. TB and Drug-resistant TB
    • 9.6.5. Gonorrhea
    • 9.6.6. HPV
    • 9.6.7. HIV
    • 9.6.8. Hepatitis C
    • 9.6.9. Hepatitis B
    • 9.6.10. COVID-19
    • 9.6.11. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.7.1. Point-of-care
    • 9.7.2. Central Laboratories
    • 9.7.3. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Infectious Disease In-vitro Diagnostics Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 10.4.1. Instruments
    • 10.4.2. Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 10.5.1. Immunoassay
    • 10.5.2. Molecular Diagnostics
    • 10.5.3. Microbiology
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.6.1. MRSA
    • 10.6.2. Clostridium Difficile
    • 10.6.3. Respiratory Virus
    • 10.6.4. TB and Drug-resistant TB
    • 10.6.5. Gonorrhea
    • 10.6.6. HPV
    • 10.6.7. HIV
    • 10.6.8. Hepatitis C
    • 10.6.9. Hepatitis B
    • 10.6.10. COVID-19
    • 10.6.11. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.7.1. Point-of-care
    • 10.7.2. Central Laboratories
    • 10.7.3. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Infectious Disease In-vitro Diagnostics Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 11.4.1. Instruments
    • 11.4.2. Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 11.5.1. Immunoassay
    • 11.5.2. Molecular Diagnostics
    • 11.5.3. Microbiology
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.6.1. MRSA
    • 11.6.2. Clostridium Difficile
    • 11.6.3. Respiratory Virus
    • 11.6.4. TB and Drug-resistant TB
    • 11.6.5. Gonorrhea
    • 11.6.6. HPV
    • 11.6.7. HIV
    • 11.6.8. Hepatitis C
    • 11.6.9. Hepatitis B
    • 11.6.10. COVID-19
    • 11.6.11. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.7.1. Point-of-care
    • 11.7.2. Central Laboratories
    • 11.7.3. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Becton, Dickinson and Company
    • 12.3.3. bioMerieux SA
    • 12.3.4. F. Hoffmann-La Roche, Ltd.
    • 12.3.5. Hologic, Inc. (Gen Probe)
    • 12.3.6. Abbott
    • 12.3.7. Quidel Corporation
    • 12.3.8. Siemens Healthineers AG
    • 12.3.9. Bio-Rad Laboratories, Inc.
    • 12.3.10. Danaher
    • 12.3.11. OraSure Technologies, Inc.
    • 12.3.12. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations